{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:55:06Z","timestamp":1768992906727,"version":"3.49.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T00:00:00Z","timestamp":1418774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T00:00:00Z","timestamp":1418774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s40262-014-0208-4","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T07:13:44Z","timestamp":1418714024000},"page":"35-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacokinetics and Pharmacokinetic\u2013Pharmacodynamic Relationships of Monoclonal Antibodies in Children"],"prefix":"10.1007","volume":"54","author":[{"given":"Helena","family":"Edlund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Melin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinnia P.","family":"Parra-Guillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,17]]},"reference":[{"key":"208_CR1","unstructured":"Pharmaceutical Research and Manufacturers of America (PhRMA). Medicines in development. Biologics 2013 report. http:\/\/www.phrma.org\/sites\/default\/files\/pdf\/biologics2013.pdf. Accessed 15 May 2014."},{"key":"208_CR2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.arcped.2010.08.026","volume":"17","author":"A Belot","year":"2010","unstructured":"Belot A, Cochat P. Les bioth\u00e9rapies en p\u00e9diatrie [Biological therapy in pediatrics] [in French]. Arch Pediatr. 2010;17:1573\u201382.","journal-title":"Arch Pediatr."},{"key":"208_CR3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633\u201359.","journal-title":"Clin Pharmacokinet."},{"key":"208_CR4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema ADR, Schellens JHM, Beijen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493\u2013507.","journal-title":"Clin Pharmacokinet."},{"key":"208_CR5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.1994.134","volume":"56","author":"G Levy","year":"1994","unstructured":"Levy G. Pharmacologic target-mediated drug disposition. Clin. Pharmacol Ther. 1994;56:248\u201352.","journal-title":"Clin. Pharmacol Ther."},{"key":"208_CR6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548\u201358.","journal-title":"Clin Pharmacol Ther."},{"key":"208_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11530560-000000000-00000","volume":"24","author":"DR Mould","year":"2010","unstructured":"Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24:23\u201339.","journal-title":"BioDrugs."},{"key":"208_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","volume":"11","author":"M Tabrizi","year":"2006","unstructured":"Tabrizi M, Tseng C, Roskos L. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81\u20138.","journal-title":"Drug Discov Today."},{"key":"208_CR9","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645\u201368.","journal-title":"J Pharm Sci."},{"key":"208_CR10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/17425255.1.3.447","volume":"1","author":"M Strolin Benedetti","year":"2005","unstructured":"Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol. 2005;1:447\u201371.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"208_CR11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0169-409X(03)00030-9","volume":"55","author":"J Alcorn","year":"2003","unstructured":"Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003;55:667\u201386.","journal-title":"Adv Drug Deliv Rev."},{"key":"208_CR12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1365-2125.2005.02445.x","volume":"59","author":"T Stephenson","year":"2005","unstructured":"Stephenson T. How children\u2019s responses to drugs differ from adults. Br J. Clin Pharmacol. 2005;59:670\u20133.","journal-title":"Br J. Clin Pharmacol."},{"key":"208_CR13","unstructured":"EMA. European public assessment reports [online database]. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124. Accessed 30 Apr 2014."},{"key":"208_CR14","unstructured":"FDA. Drugs@FDA [online database]. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?CFID=27729622&CFTOKEN=dde04172480c4c9e-D1772092-D394-B5A6-256F39805045CED6#labelinfo. Accessed 30 Apr 2014."},{"key":"208_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1472-8206.2003.00123.x","volume":"17","author":"L Cuzzolin","year":"2003","unstructured":"Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol. 2003;17:125\u201331.","journal-title":"Fundam Clin Pharmacol."},{"key":"208_CR16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-150-5-200903030-00108","volume":"150","author":"MR Gillick","year":"2009","unstructured":"Gillick MR. Controlling off-label medication use. Ann Intern Med. 2009;150:344\u20137.","journal-title":"Ann Intern Med."},{"key":"208_CR17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytu\u0142a","year":"2010","unstructured":"Prytu\u0142a A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461\u20138.","journal-title":"Pediatr Nephrol."},{"key":"208_CR18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/imj.12206","volume":"43","author":"K O\u2019Connor","year":"2013","unstructured":"O\u2019Connor K, Liddle C. Prospective data collection of off-label use of rituximab in Australian public hospitals. Intern Med J. 2013;43:863\u201370.","journal-title":"Intern Med J."},{"key":"208_CR19","doi-asserted-by":"crossref","first-page":"e36698","DOI":"10.1371\/journal.pone.0036698","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One. 2012;7:e36698.","journal-title":"PLoS One."},{"key":"208_CR20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kes373","volume":"52","author":"J Anink","year":"2013","unstructured":"Anink J, Otten MH, Prince FHM, Hoppenreijs EPAH, Wulffraat NM, Swart JF, et al. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatology. 2013;52:712\u20137.","journal-title":"Rheumatology."},{"key":"208_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/ard.2010.135731","volume":"70","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FHM, ten Cate R, van Rossum MAJ, Twilt M, Hoppenreijs EPAH, et al. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis. 2011;70:337\u201340.","journal-title":"Ann Rheum Dis."},{"key":"208_CR22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/INF.0b013e3181673c15","volume":"27","author":"ME Speer","year":"2008","unstructured":"Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J. 2008;27:559\u201361.","journal-title":"Pediatr Infect Dis J."},{"key":"208_CR23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","volume":"153","author":"JC Burns","year":"2008","unstructured":"Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153:833\u20138.","journal-title":"J Pediatr."},{"key":"208_CR24","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMc1308488","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014;370:1268\u201370.","journal-title":"N Engl J Med."},{"key":"208_CR25","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJMhpr021646","volume":"347","author":"R Steinbrook","year":"2002","unstructured":"Steinbrook R. Testing medications in children. N Engl J Med. 2002;347:1462\u201370.","journal-title":"N Engl J Med."},{"key":"208_CR26","unstructured":"EMA, Paediatric Committee. Medicines for children. Paediatric investigation plans; 2007. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000302.jsp&mid=WC0b01ac058002d4ea. Accessed 13 May 2014."},{"key":"208_CR27","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Draft guidance for industry. Pediatric Study Plans: Content of and process for submitting. Initial pediatric study plans and amended pediatric study plans. Draft guidance. July 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM360507.pdf. Accessed 13 May 2014."},{"issue":"Suppl 1","key":"208_CR28","first-page":"S88","volume":"93","author":"X Zhang","year":"2013","unstructured":"Zhang X, Hsu J, Brunner H, De Benedetti F, Le Gallo C, Zuber Z, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in polyarticular-course juvenile idiopathic arthritis (pcJIA). Clin Pharmacol Ther. 2013;93(Suppl 1):S88\u20139.","journal-title":"Clin Pharmacol Ther."},{"key":"208_CR29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/adc.2006.114835","volume":"93","author":"TN Johnson","year":"2008","unstructured":"Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child. 2008;93:207\u201311.","journal-title":"Arch Dis Child."},{"key":"208_CR30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/pharmaceutics2040389","volume":"2","author":"R Shi","year":"2010","unstructured":"Shi R, Derendorf H. Pediatric dosing and body size in biotherapeutics. Pharmaceutics. 2010;2:389\u2013418.","journal-title":"Pharmaceutics."},{"key":"208_CR31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"208_CR32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25\u201336.","journal-title":"Drug Metab Pharmacokinet."},{"key":"208_CR33","first-page":"1098","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.","journal-title":"N Engl J Med."},{"key":"208_CR34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","volume":"93","author":"GB Haycock","year":"1978","unstructured":"Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93:62\u20136.","journal-title":"J Pediatr."},{"key":"208_CR35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D Du Bois","year":"1916","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863\u201371.","journal-title":"Arch Intern Med."},{"key":"208_CR36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","volume":"52","author":"M Dostalek","year":"2013","unstructured":"Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52:83\u2013124.","journal-title":"Clin Pharmacokinet."},{"key":"208_CR37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2012.10.005","volume":"137","author":"Z Xu","year":"2013","unstructured":"Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137:225\u201347.","journal-title":"Pharmacol Ther."},{"key":"208_CR38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14:559\u201370.","journal-title":"AAPS J."},{"key":"208_CR39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/dmd.112.048496","volume":"41","author":"L Kagan","year":"2013","unstructured":"Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos. 2013;41:248\u201355.","journal-title":"Drug Metab Dispos."},{"key":"208_CR40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/9783527609628.ch3","volume-title":"Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development","author":"K Kuester","year":"2006","unstructured":"Kuester K, Kloft C. Pharmacokinetics of monoclonal antibodies (part I and II). In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2006. p. 45\u201391."},{"key":"208_CR41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","volume":"72","author":"PJ Lowe","year":"2011","unstructured":"Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol. 2011;72:306\u201320.","journal-title":"Br J Clin Pharmacol."},{"key":"208_CR42","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","volume":"56","author":"GJ Robbie","year":"2012","unstructured":"Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927\u201336.","journal-title":"Antimicrob Agents Chemother."},{"key":"208_CR43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10928-009-9120-1","volume":"36","author":"B-F Krippendorff","year":"2009","unstructured":"Krippendorff B-F, Kuester K, Kloft C, Huisinga W. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn. 2009;36:239\u201360.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"208_CR44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0165-5728(01)00242-9","volume":"114","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol. 2001;114:168\u201372.","journal-title":"J Neuroimmunol."},{"key":"208_CR45","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1203\/00006450-200005000-00004","volume":"47","author":"NF Butte","year":"2000","unstructured":"Butte NF, Hopkinson JM, Wong WW, O\u2019Brian Smith E, Ellis KJ. Body composition during the first 2\u00a0years of life: an updated reference. Pediatr Res. 2000;47:578\u201385.","journal-title":"Pediatr Res."},{"key":"208_CR46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.ftd.0000189901.08684.4b","volume":"28","author":"D Ternant","year":"2006","unstructured":"Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin J-M, Watier H, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169\u201374.","journal-title":"Ther Drug Monit."},{"key":"208_CR47","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715\u201325.","journal-title":"Nat Rev Immunol."},{"key":"208_CR48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11596370-000000000-00000","volume":"51","author":"S Bai","year":"2012","unstructured":"Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51:119\u201335.","journal-title":"Clin Pharmacokinet."},{"key":"208_CR49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","volume":"48","author":"A Fasanmade","year":"2010","unstructured":"Fasanmade A, Adedokun O, Olson A, Strauss R, Davis H. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol. Ther. 2010;48:297\u2013308.","journal-title":"Int J Clin Pharmacol. Ther."},{"key":"208_CR50","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946\u201364.","journal-title":"Clin Ther."},{"key":"208_CR51","first-page":"197","volume":"30","author":"N Kapel","year":"1992","unstructured":"Kapel N, Meillet D, Favennec L, Magne D, Raichvarg D, Gobert JG. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn\u2019s disease and ulcerative colitis. Eur J Clin Chem Clin Biochem. 1992;30:197\u2013202.","journal-title":"Eur J Clin Chem Clin Biochem."},{"key":"208_CR52","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S1873-9946(13)60521-8","volume":"7","author":"JF Brandse","year":"2013","unstructured":"Brandse JF, Wildenberg ME, de Bruyn JR, Wolbink G, Lowenberg M, Ponsioen CY, et al. P500 Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease [abstract]. J Crohns Colitis. 2013;7:S210.","journal-title":"J Crohns Colitis"},{"key":"208_CR53","unstructured":"Struemper H, Cai W. Population pharmacokinetics of belimumab in systemic lupus erythematosus: insights for monoclonal antibody covariate modeling from a large data set [abstract no. 2792]. PAGE 22; 11\u201314 Jun 2013; Glasgow. http:\/\/www.page-meeting.org\/?abstract=2792. Accessed 22 Oct 2014."},{"key":"208_CR54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","volume":"24","author":"MM Rhodin","year":"2009","unstructured":"Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24:67\u201376.","journal-title":"Pediatr Nephrol."},{"key":"208_CR55","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1034\/j.1398-9995.2000.00118.x","volume":"55","author":"PG Holt","year":"2000","unstructured":"Holt PG, Jones CA. The development of the immune system during pregnancy and early life. Allergy. 2000;55:688\u201397.","journal-title":"Allergy."},{"key":"208_CR56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1081-1206(10)60665-5","volume":"99","author":"S Agarwal","year":"2007","unstructured":"Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99:281\u20133.","journal-title":"Ann Allergy Asthma Immunol."},{"key":"208_CR57","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.iac.2008.07.001","volume":"28","author":"M Garcia-Lloret","year":"2008","unstructured":"Garcia-Lloret M, McGhee S, Chatila T. Immunoglobulin replacement therapy in children. Immunol Allergy Clin N Am. 2008;28:833\u201349.","journal-title":"Immunol Allergy Clin N Am."},{"key":"208_CR58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","volume":"68","author":"PJ Lowe","year":"2009","unstructured":"Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68:61\u201376.","journal-title":"Br J Clin Pharmacol."},{"key":"208_CR59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5455\/apr.042120121033","volume":"1","author":"J Goldman","year":"2012","unstructured":"Goldman J, Davis H, Zhou H, Kearns G. Infliximab clearance in children: potential association with resting energy expenditure. Ann Paediatr Rheum. 2012;1:120\u20135.","journal-title":"Ann Paediatr Rheum."},{"key":"208_CR60","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00007890-200210150-00011","volume":"74","author":"JM Kovarik","year":"2002","unstructured":"Kovarik JM, Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation. 2002;74:966\u201371.","journal-title":"Transplantation."},{"key":"208_CR61","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry and FDA staff. Qualification process for drug development tools. Jan 2014. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM230597.pdf. Accessed 14 Feb 2014."},{"key":"208_CR62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"208_CR63","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1128\/AAC.01565-08","volume":"53","author":"LE Weisman","year":"2009","unstructured":"Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1\/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2009;53:2879\u201386.","journal-title":"Antimicrob Agents Chemother."},{"key":"208_CR64","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1203\/00006450-201011001-01380","volume":"68","author":"JF Kokai-Kun","year":"2010","unstructured":"Kokai-Kun JF, Mould D, Weisman L, Bloom B, Eyal F, Polack M, et al. Predicted and measured pagibaximab serum levels in high-risk neonates [poster no. 1380]. Pediatr Res. 2010;68:683.","journal-title":"Pediatr Res."},{"key":"208_CR65","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/TP.0b013e318188ae18","volume":"86","author":"B H\u00f6cker","year":"2008","unstructured":"H\u00f6cker B, Kovarik JM, Daniel V, Opelz G, Fehrenbach H, Holder M, et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation. 2008;86:1234\u201340.","journal-title":"Transplantation."},{"key":"208_CR66","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5414\/CPP48214","volume":"48","author":"T Nagai","year":"2010","unstructured":"Nagai T, Gotoh Y, Watarai Y, Tajima T, Arai K, Uchida K. Pharmacokinetics and pharmacodynamics of basiliximab in Japanese pediatric renal transplant patients. Int J Clin Pharmacol Ther. 2010;48:214\u201323.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"208_CR67","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","volume":"28","author":"AS De Groot","year":"2007","unstructured":"De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28:482\u201390.","journal-title":"Trends Immunol."},{"key":"208_CR68","doi-asserted-by":"crossref","first-page":"vi3","DOI":"10.1093\/ndt\/gfh1092","volume":"20","author":"H Schellekens","year":"2005","unstructured":"Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20:vi3\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"208_CR69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/157488610792246055","volume":"5","author":"R Niebecker","year":"2010","unstructured":"Niebecker R, Kloft C. Safety of therapeutic monoclonal antibodies. Curr Drug Saf. 2010;5:275\u201386.","journal-title":"Curr Drug Saf."},{"key":"208_CR70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 2012;14:296\u2013302.","journal-title":"AAPS J."},{"key":"208_CR71","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm338856.pdf. Accessed 22 Oct 2014."},{"key":"208_CR72","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond R, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2004;2:542\u201353.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"208_CR73","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases. Ann Rheum Dis. 2013;72:165\u201378.","journal-title":"Ann Rheum Dis."},{"key":"208_CR74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","volume":"382","author":"S-L Wang","year":"2012","unstructured":"Wang S-L, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382:177\u201388.","journal-title":"J Immunol Methods."},{"key":"208_CR75","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Mantilla JD, Troc\u00f3niz IF, Parra-Guill\u00e9n Z, Garrido MJ. Review on modeling anti-antibody responses to monoclonal antibodies. J Pharmacokinet Pharmacodyn. Epub 2014 Jul 16.","DOI":"10.1007\/s10928-014-9367-z"},{"key":"208_CR76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","volume":"9","author":"C-A Siegrist","year":"2009","unstructured":"Siegrist C-A, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009;9:185\u201394.","journal-title":"Nat Rev Immunol."},{"key":"208_CR77","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","volume":"53","author":"AL Angiolillo","year":"2009","unstructured":"Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a children\u2019s oncology group report. Pediatr Blood Cancer. 2009;53:978\u201383.","journal-title":"Pediatr Blood Cancer."},{"key":"208_CR78","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Haweekins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70:2095\u2013102.","journal-title":"Ann Rheum Dis."},{"key":"208_CR79","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416\u201325.","journal-title":"N Engl J Med."},{"key":"208_CR80","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med."},{"key":"208_CR81","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557\u201367.","journal-title":"Arthritis Rheum."},{"key":"208_CR82","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","volume":"98","author":"R Baldassano","year":"2003","unstructured":"Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn\u2019s disease. Am J Gastroenterol. 2003;98:833\u20138.","journal-title":"Am J Gastroenterol."},{"key":"208_CR83","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00005176-199910000-00169","volume":"29","author":"C Hadigan","year":"1999","unstructured":"Hadigan C, Baldassano R, Braegger CP, Vasiliauskis E, Escher JC, Sinaasappel M, et al. Pharmacokinetics of infliximab (Anti-TNF) in children with Crohn\u2019s disease: a multicenter trial [abstract]. J Pediatr Gastroenterol Nutr. 1999;29:525.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"208_CR84","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/INF.0b013e31818ffd03","volume":"28","author":"K Abarca","year":"2009","unstructured":"Abarca K, Jung E, Fern\u00e1ndez P, Zhao L, Harris B, Connor EM, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J. 2009;28:267\u201372.","journal-title":"Pediatr Infect Dis J."},{"key":"208_CR85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1542\/peds.2010-3081","volume":"128","author":"LE Weisman","year":"2011","unstructured":"Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011;128:271\u20139.","journal-title":"Pediatrics."},{"key":"208_CR86","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/322043","volume":"184","author":"M Boeckh","year":"2001","unstructured":"Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350\u20134.","journal-title":"J Infect Dis."},{"key":"208_CR87","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810\u201320.","journal-title":"N Engl J Med."},{"key":"208_CR88","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","volume":"31","author":"T Imagawa","year":"2012","unstructured":"Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31:1713\u201321.","journal-title":"Clin Rheumatol."},{"key":"208_CR89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","volume":"143","author":"JS Hyams","year":"2012","unstructured":"Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children. Gastroenterology. 2012;143:365\u201374.","journal-title":"Gastroenterology."},{"key":"208_CR90","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.ajkd.2009.08.019","volume":"55","author":"MS Joy","year":"2010","unstructured":"Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, et al. Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010;55:50\u201360.","journal-title":"Am J Kidney Dis."},{"key":"208_CR91","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s10067-014-2498-1","volume":"33","author":"DJ Kingsbury","year":"2014","unstructured":"Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2\u20134\u00a0years. Clin. Rheumatol. 2014;33:4133\u201341.","journal-title":"Clin. Rheumatol."},{"key":"208_CR92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","volume":"26","author":"JL Glade Bender","year":"2008","unstructured":"Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children\u2019s oncology group study. J Clin Oncol. 2008;26:399\u2013405.","journal-title":"J Clin Oncol"},{"key":"208_CR93","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1200\/JCO.2008.20.8975","volume":"27","author":"TM Trippett","year":"2009","unstructured":"Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators\u2019 consortium. J Clin Oncol. 2009;27:5102\u20138.","journal-title":"J Clin Oncol."},{"key":"208_CR94","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","volume":"30","author":"S Malempati","year":"2012","unstructured":"Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30:256\u201362.","journal-title":"J Clin Oncol."},{"key":"208_CR95","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169\u201381.","journal-title":"N Engl J Med."},{"key":"208_CR96","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0091270004267595","volume":"44","author":"M Buckwalter","year":"2004","unstructured":"Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44:873\u201380.","journal-title":"J Clin Pharmacol."},{"key":"208_CR97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2005.07.010","volume":"118","author":"S Candon","year":"2006","unstructured":"Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, C\u00e9zard J-P. Clinical and biological consequences of immunization to infliximab in pediatric Crohn\u2019s disease. Clin Immunol. 2006;118:11\u20139.","journal-title":"Clin Immunol."},{"key":"208_CR98","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/01.MIB.0000435438.84365.f7","volume":"19","author":"OJ Adedokun","year":"2013","unstructured":"Adedokun OJ, Xu Z, Padgett L, Blank M, Johanns J, Griffiths A, et al. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflamm Bowel Dis. 2013;19:2753\u201362.","journal-title":"Inflamm Bowel Dis."},{"key":"208_CR99","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132:863\u201373 (quiz 1165\u20136).","journal-title":"Gastroenterology"},{"key":"208_CR100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1185\/03007995.2010.547575","volume":"27","author":"J Hyams","year":"2011","unstructured":"Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn\u2019s disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27:651\u201362.","journal-title":"Curr Med Res Opin."},{"key":"208_CR101","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096\u2013106.","journal-title":"Arthritis Rheum."},{"key":"208_CR102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2431-10-38","volume":"10","author":"P Fern\u00e1ndez","year":"2010","unstructured":"Fern\u00e1ndez P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010;10:38.","journal-title":"BMC Pediatr."},{"key":"208_CR103","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/01.mpg.0000182003.06031.00","volume":"41","author":"J Grundy","year":"2005","unstructured":"Grundy J, Pan W, Kugathasan S, Nagpala F, Hilton D, Taylor J, et al. Pharmacokinetics and pharmacodynamics of natalizumab in a phase 2 study of adolescent patients with Crohn\u2019s disease. J Pediatr Gastroenterol Nutr. 2005;41:493\u2013563.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"208_CR104","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/01.mpg.0000252191.05170.e7","volume":"44","author":"JS Hyams","year":"2007","unstructured":"Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr. 2007;44:185\u201391.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"208_CR105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.inf.0000133165.85909.08","volume":"23","author":"X S\u00e1ez-Llorens","year":"2004","unstructured":"S\u00e1ez-Llorens X, Moreno MT, Ramilo O, S\u00e1nchez PJ, Top FH, Connor EM. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707\u201312.","journal-title":"Pediatr Infect Dis J."},{"key":"208_CR106","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00006454-199809000-00007","volume":"17","author":"X S\u00e1ez-Llorens","year":"1998","unstructured":"S\u00e1ez-Llorens X, Casta\u00f1o E, Null D, Steichen J, S\u00e1nchez PJ, Ramilo O, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:787\u201391.","journal-title":"Pediatr Infect Dis J."},{"key":"208_CR107","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","volume":"17","author":"KN Subramanian","year":"1998","unstructured":"Subramanian KN, Weisman LE, Rhodes T, Ariagno R, S\u00e1nchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:110\u20135.","journal-title":"Pediatr Infect Dis J."},{"key":"208_CR108","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.12434","volume":"162","author":"MJ Barth","year":"2013","unstructured":"Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma\/leukaemia: a children\u2019s oncology group report. Br J Haematol. 2013;162:678\u201383.","journal-title":"Br J Haematol."},{"key":"208_CR109","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MPH.0b013e3181cf0726","volume":"32","author":"MR Pranzatelli","year":"2010","unstructured":"Pranzatelli MR, Tate ED, Verhulst SJ, Bertolone SJ, Bhatla D, Granger M, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2010;32:e167\u201372.","journal-title":"J Pediatr Hematol Oncol."},{"key":"208_CR110","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol."},{"key":"208_CR111","doi-asserted-by":"crossref","first-page":"s682","DOI":"10.1002\/art.34426","volume":"64","author":"H Brunner","year":"2012","unstructured":"Brunner H, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial [abstract no. 1597]. Arthritis Rheum. 2012;64:s682.","journal-title":"Arthritis Rheum."},{"key":"208_CR112","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"P Woo","year":"2005","unstructured":"Woo P, Wilkinson N, Prieur A-M, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281\u20138.","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"208_CR113","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/ecp.13.1","volume":"6","author":"X Zhang","year":"2013","unstructured":"Zhang X, Morcos PN, Saito T, Terao K. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2013;6(2):123\u201337.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"208_CR114","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998\u20131006.","journal-title":"Lancet."},{"issue":"10","key":"208_CR115","first-page":"381e","volume":"31","author":"X Zhang","year":"2011","unstructured":"Zhang X, Morcos PN, De Benedetti F, Brunner H, Ruperto N, Schaefer F, et al. Pharmacokinetics and pharmacodynamics of tocilizumab in systemic juvenile idiopathic arthritis [abstract]. Pharmacotherapy. 2011;31(10):381e.","journal-title":"Pharmacotherapy."},{"key":"208_CR116","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1007\/s11095-011-0481-y","volume":"28","author":"T Kakkar","year":"2011","unstructured":"Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin S-L, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;28:2530\u201342.","journal-title":"Pharm Res."},{"key":"208_CR117","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/1078-0432.CCR-13-2364","volume":"20","author":"DC Turner","year":"2014","unstructured":"Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, et al. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res. 2014;20:2783\u201392.","journal-title":"Clin Cancer Res."},{"key":"208_CR118","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1399-3046.2007.00830.x","volume":"12","author":"MD Pescovitz","year":"2008","unstructured":"Pescovitz MD, Knechtle S, Alexander SR, Colombani P, Nevins T, Nieforth K, et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant. 2008;12:447\u201355.","journal-title":"Pediatr Transplant."},{"key":"208_CR119","first-page":"203","volume":"4","author":"Z Xu","year":"2012","unstructured":"Xu Z, Mould D, Hu C, Ford J, Keen M, Davis HM, et al. Population pharmacokinetic analysis of infliximab in pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;4:203.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"208_CR120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1203\/00006450-201011001-00891","volume":"68","author":"L Zhao","year":"2010","unstructured":"Zhao L, Roskos L, Griffin P, Losonsky G, Jallal GB, Robbie G. 891 Population pharmacokinetics analysis of motavizumab in children at risk for respiratory syncytial virus infection. Pediatr. Res. 2010;68:447.","journal-title":"Pediatr. Res."},{"key":"208_CR121","doi-asserted-by":"crossref","first-page":"P7","DOI":"10.1067\/mcp.2001.112364","volume":"69","author":"M Marian","year":"2001","unstructured":"Marian M, Sun Y-N, Sinclair D, Kenkare S, Sallas W, Mortensen D, et al. PI-23 Clincal pharmacokinetics (PK) and IgE pharmacodynamics (PD) of omalizumab, a recombinant humanized monoclonal antibody to IgE. Clin Pharmacol Ther. 2001;69:P7.","journal-title":"Clin Pharmacol Ther."},{"key":"208_CR122","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","volume":"107","author":"CM Bennett","year":"2006","unstructured":"Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639\u201342.","journal-title":"Blood."},{"key":"208_CR123","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","volume":"62","author":"W Hagopian","year":"2013","unstructured":"Hagopian W, Ferry RJ, Sherry N, Carlin D, Bonvini E, Johnson S, et al. Teplizumab preserves C-Peptide in recent-onset type 1 diabetes. Two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial. Diabetes. 2013;62:3901\u20138.","journal-title":"Diabetes."},{"key":"208_CR124","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","volume":"378","author":"N Sherry","year":"2011","unstructured":"Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, et al. Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378:487\u201397.","journal-title":"Lancet."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-014-0208-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0208-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:19:39Z","timestamp":1659100779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-014-0208-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0208-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,17]]},"assertion":[{"value":"17 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}